ABVX:EPA
Abivax SA
€76.05
arrow_upward
+0.73%(+0.55) 1D
Nov 18, 9:43:16 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€75.50
High
€76.05
Low
€75.10
Mkt. cap
6.66B
Avg. vol.
109.70K
Volume
5.06K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€75.50
High
€76.05
Low
€75.10
Mkt. cap
6.66B
Avg. vol.
109.70K
Volume
5.06K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
MarketWatch
·
16 minutes ago
The S&P 500 just broke a crucial support level. Here’s what history shows may happen now.
TradingView
·
1 hour ago
SPX: S&P 500 Futures Edge Higher After Four-Day Slide, Nvidia Earnings Buoy Tech Stocks
ChartMill
·
11 hours ago
S&P 500 After-Hours Gainers for Nov. 17, 2026
Benzinga
·
2 hours ago
Stock Market: Will S&P 500 Open Up or Down Today?
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com